# Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis

> **NCT07169682** · — · COMPLETED · sponsor: **National and Kapodistrian University of Athens** · enrollment: 66 (actual)

## Conditions studied

- Psoriasis
- Cardiovascular Disease
- Atherosclerosis

## Interventions

- **DRUG:** interleukin 17 inhibitor
- **DRUG:** interleukin-23 inhibitor
- **DRUG:** conventional systemic agent or apremilast

## Key facts

- **NCT ID:** NCT07169682
- **Lead sponsor:** National and Kapodistrian University of Athens
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169682, "Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07169682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*